|
Apr 3
|
Aligos Therapeutics Announces First Subjects Dosed in the Phase 2a HERALD Study of ALG-055009 in MASH Subjects
|
|
Mar 27
|
Aligos Therapeutics, Inc. (ALGS) Just Flashed Golden Cross Signal: Do You Buy?
|
|
Mar 27
|
Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 Studies
|
|
Mar 18
|
Aligos Therapeutics Announces the Initiation of the Phase 2a HERALD Study of ALG-055009 in MASH Subjects
|
|
Mar 14
|
Aligos Therapeutics Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag
|
|
Mar 12
|
Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial Results
|
|
Mar 5
|
Aligos Therapeutics to Announce 4th Quarter 2023 Financial Results on March 12, 2024
|
|
Feb 26
|
Aligos Therapeutics To Participate in the Leerink Partners Global Biopharma Conference 2024
|
|
Feb 20
|
Aligos Therapeutics to Host KOL Event to Discuss Phase 2a HERALD Study of ALG-055009 in MASH on March 7, 2024
|
|
Jan 5
|
Is Aligos Therapeutics (ALGS) Stock Outpacing Its Medical Peers This Year?
|
|
Dec 7
|
Aligos Therapeutics Presents Positive Clinical Data at Hep-DART 2023 from Phase 1 Studies in HBV (ALG-000184) and NASH (ALG-055009)
|
|
Nov 13
|
Aligos Therapeutics Presents Clinical and Nonclinical Data at the AASLD Liver Meeting® 2023 Demonstrating that ALG-055009 has a Favorable Risk-Benefit Profile
|
|
Nov 10
|
Aligos Therapeutics Presents Positive Data at the AASLD Liver Meeting® 2023 Demonstrating that Treatment with ALG-000184 (CAM-E) Results in Significant Multi-log Reductions in Hepatitis B Antigens (HBsAg, HBcrAg and HBeAg)
|
|
Nov 7
|
Aligos Therapeutics to Present Multiple Posters at AASLD’s The Liver Meeting® 2023, Highlighting Progress for Its Clinical Stage Portfolio, including Lead THR-β Agonist for the Treatment of NASH, ALG-055009; ALG-000184, the Company’s Lead CAM-E Molecul...
|
|
Nov 3
|
Aligos Therapeutics to Host KOL Event to Discuss ALG-000184 Phase 1, AASLD Late Breaker Data
|
|
Nov 2
|
Aligos Therapeutics Inc (ALGS) Reports Q3 2023 Financial Results and Business Progress
|
|
Nov 2
|
Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2023 Financial Results
|
|
Sep 21
|
Aligos Therapeutics Announces IND Clearance for NASH lead, ALG-055009
|
|
Jul 19
|
Aligos Therapeutics Announces the Selection of Stephen Harrison, MD as Principal Investigator of Ph2a Study and Key Study Design Elements/Milestones for NASH Drug Candidate, ALG-055009
|
|
May 24
|
Aligos Therapeutics to Present at the Jefferies 2023 Healthcare Conference
|